Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Venus Remedies Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Şu anda Venus Remedies için büyüme ve gelir tahmini yapmak üzere yeterli analist kapsamımız yok.

Anahtar bilgiler

n/a

Kazanç büyüme oranı

n/a

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	18.5%
Gelir büyüme oranı	n/a
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	None
Son güncelleme	n/a

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

Shareholders May Not Be So Generous With Venus Remedies Limited's (NSE:VENUSREM) CEO Compensation And Here's Why

Sep 17

Venus Remedies Limited (NSE:VENUSREM) Held Back By Insufficient Growth Even After Shares Climb 26%

Jun 14

Venus Remedies (NSE:VENUSREM) Could Easily Take On More Debt

Jun 13

Venus Remedies Limited (NSE:VENUSREM) Not Doing Enough For Some Investors As Its Shares Slump 26%

Mar 14

I Ran A Stock Scan For Earnings Growth And Venus Remedies (NSE:VENUSREM) Passed With Ease

Mar 30

Why Investors Shouldn't Be Surprised By Venus Remedies Limited's (NSE:VENUSREM) 25% Share Price Plunge

Feb 24

Is Venus Remedies (NSE:VENUSREM) Using Too Much Debt?

Feb 01

Here's Why We Think Venus Remedies (NSE:VENUSREM) Is Well Worth Watching

Nov 16

Venus Remedies Limited's (NSE:VENUSREM) Stock Is Going Strong: Have Financials A Role To Play?

Mar 11

We Think Venus Remedies (NSE:VENUSREM) Is Taking Some Risk With Its Debt

Jan 14

Does Venus Remedies's (NSE:VENUSREM) Statutory Profit Adequately Reflect Its Underlying Profit?

Nov 23

Is Venus Remedies (NSE:VENUSREM) A Risky Investment?

Sep 22

Bu bölümde, yatırımcıların şirketin kâr elde etme kabiliyetini anlamalarına yardımcı olmak için genellikle profesyonel analistlerin fikir birliği tahminlerine dayanan gelir ve kazanç büyüme tahminlerini sunuyoruz. Ancak Venus Remedies yeterli geçmiş veri sağlamadığından ve analist tahmini olmadığından, gelecekteki kazançları geçmiş verileri ekstrapole ederek veya analist tahminlerini kullanarak güvenilir bir şekilde hesaplanamaz.

SimplyWall St tarafından kapsanan şirketlerin %97'si geçmiş finansal verilere sahip olduğu için bu oldukça nadir bir durumdur.

Kazanç ve Gelir Büyüme Tahminleri

NSEI:VENUSREM - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (INR Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
6/30/2024	6,149	285	N/A	N/A	N/A
3/31/2024	6,014	285	238	373	N/A
12/31/2023	5,619	290	N/A	N/A	N/A
9/30/2023	5,354	255	67	150	N/A
6/30/2023	5,076	209	N/A	N/A	N/A
3/31/2023	5,555	266	288	366	N/A
12/31/2022	5,418	157	N/A	N/A	N/A
9/30/2022	5,492	181	230	329	N/A
6/30/2022	6,119	359	N/A	N/A	N/A
3/31/2022	6,002	407	274	411	N/A
12/31/2021	5,702	756	N/A	N/A	N/A
9/30/2021	5,684	816	809	681	N/A
6/30/2021	5,087	715	N/A	N/A	N/A
3/31/2021	5,481	618	1,241	1,318	N/A
12/31/2020	5,320	213	N/A	N/A	N/A
9/30/2020	4,939	87	1,156	1,196	N/A
6/30/2020	4,586	-40	N/A	N/A	N/A
3/31/2020	3,407	-100	698	776	N/A
12/31/2019	3,490	-161	N/A	N/A	N/A
9/30/2019	3,281	-269	506	596	N/A
6/30/2019	3,286	-269	N/A	N/A	N/A
3/31/2019	3,219	-286	354	453	N/A
3/31/2018	3,724	-307	N/A	312	N/A
3/31/2017	4,000	-171	N/A	589	N/A
3/31/2016	4,183	17	N/A	469	N/A
3/31/2015	4,640	52	N/A	678	N/A
3/31/2014	5,416	643	N/A	526	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: VENUSREM 'un tahmini kazanç büyümesinin tasarruf oranının ( 6.7% ) üzerinde olup olmadığını belirlemek için yeterli veri yok.

Kazançlar ve Piyasa: VENUSREM 'un kazançlarının Indian pazarından daha hızlı büyümesinin öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Yüksek Büyüme Kazançları: VENUSREM şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artıp artmayacağını belirlemek için yeterli veri bulunmuyor.

Gelir ve Pazar: VENUSREM şirketinin gelirinin Indian pazarından daha hızlı büyüyeceğinin tahmin edilip edilmediğini belirlemek için yeterli veri yok.

Yüksek Büyüme Geliri: VENUSREM şirketinin gelirinin yıllık 20% oranından daha hızlı artacağının tahmin edilip edilmediğini belirlemek için yeterli veri yok.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: VENUSREM 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Venus Remedies Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Recent updates

Venus Remedies Limited to Report First Half, 2025 Results on Oct 29, 2024

Now 22% undervalued after recent price drop

Venus Remedies Limited Announces Executive Appointments

Shareholders May Not Be So Generous With Venus Remedies Limited's (NSE:VENUSREM) CEO Compensation And Here's Why

Venus Remedies Limited to Report Q2, 2025 Results on Nov 14, 2024

Venus Remedies Limited, Annual General Meeting, Sep 23, 2024

First quarter 2025 earnings released: EPS: ₹0.92 (vs ₹0.88 in 1Q 2024)

Venus Remedies Limited to Report Q1, 2025 Results on Aug 13, 2024

Now 24% overvalued after recent price rise

Now 21% overvalued after recent price rise

Now 21% overvalued after recent price rise

Venus Remedies Limited (NSE:VENUSREM) Held Back By Insufficient Growth Even After Shares Climb 26%

Now 27% overvalued after recent price rise

Venus Remedies (NSE:VENUSREM) Could Easily Take On More Debt

Investor sentiment improves as stock rises 17%

Full year 2024 earnings released: EPS: ₹21.31 (vs ₹19.87 in FY 2023)

Venus Remedies Limited to Report Q4, 2024 Results on May 30, 2024

Investor sentiment improves as stock rises 16%

Venus Remedies Limited (NSE:VENUSREM) Not Doing Enough For Some Investors As Its Shares Slump 26%

Third quarter 2024 earnings released: EPS: ₹5.13 (vs ₹2.46 in 3Q 2023)

Venus Remedies Limited to Report Q3, 2024 Results on Feb 14, 2024

Second quarter 2024 earnings released: EPS: ₹7.44 (vs ₹3.99 in 2Q 2023)

Investor sentiment improves as stock rises 23%

Calculating The Fair Value Of Venus Remedies Limited (NSE:VENUSREM)

Venus Remedies Limited to Report Q2, 2024 Results on Nov 09, 2023

New minor risk - Share price stability

Investor sentiment improves as stock rises 19%

Now 20% undervalued after recent price drop

Venus Remedies Limited Receives Marketing Approval from the Philippines for Six Key Chemotherapy Drugs

Investor sentiment deteriorates as stock falls 15%

New minor risk - Profit margin trend

Venus Remedies Limited to Report Q1, 2024 Results on Aug 14, 2023

Full year 2023 earnings released: EPS: ₹19.87 (vs ₹30.86 in FY 2022)

Venus Remedies Limited, Annual General Meeting, Aug 24, 2023

Investor sentiment improves as stock rises 15%

Venus Remedies Limited Receives Ukrainian GMP Approval for Its Carbapenem, Oncology Parenteral Facilities

Venus Remedies (NSE:VENUSREM) Seems To Use Debt Rather Sparingly

Full year 2023 earnings released: EPS: ₹19.88 (vs ₹30.86 in FY 2022)

Investor sentiment improves as stock rises 18%

Investor sentiment improves as stock rises 20%

Less than half of directors are independent

Third quarter 2023 earnings released: EPS: ₹2.46 (vs ₹4.22 in 3Q 2022)

Second quarter 2023 earnings released: EPS: ₹3.99 (vs ₹17.32 in 2Q 2022)

First quarter 2023 earnings released: EPS: ₹5.16 (vs ₹8.86 in 1Q 2022)

Venus Remedies Limited to Report Q2, 2023 Results on Nov 14, 2022

Venus Remedies Limited, Annual General Meeting, Aug 23, 2022

Venus Remedies Limited to Report Q1, 2023 Results on Jul 30, 2022

Now 21% undervalued after recent price drop

Estimating The Fair Value Of Venus Remedies Limited (NSE:VENUSREM)

Now 25% undervalued after recent price drop

Chairman recently bought ₹28m worth of stock

Is Venus Remedies (NSE:VENUSREM) Using Too Much Debt?

Now 19% undervalued after recent price drop

Full year 2022 earnings released: EPS: ₹30.86 (vs ₹50.05 in FY 2021)

Venus Remedies Limited Appoints Akshansh Chaudhary as Additional Director (Whole Time Director)

Investor sentiment improved over the past week

Venus Remedies Limited to Report Q4, 2022 Results on May 27, 2022

Investor sentiment improved over the past week

I Ran A Stock Scan For Earnings Growth And Venus Remedies (NSE:VENUSREM) Passed With Ease

Why Investors Shouldn't Be Surprised By Venus Remedies Limited's (NSE:VENUSREM) 25% Share Price Plunge

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Is Venus Remedies (NSE:VENUSREM) Using Too Much Debt?

Investor sentiment deteriorated over the past week

Here's Why We Think Venus Remedies (NSE:VENUSREM) Is Well Worth Watching

Second quarter 2022 earnings released: EPS ₹17.32 (vs ₹10.55 in 2Q 2021)

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS ₹8.86 (vs ₹6.08 in 1Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS ₹50.04 (vs ₹8.10 loss in FY 2020)

Venus Remedies Limited announced that it has received INR 137.52425 million in funding

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Venus Remedies Limited's (NSE:VENUSREM) Stock Is Going Strong: Have Financials A Role To Play?

New 90-day high: ₹228